Formic Acid

Formic Acid

SCHEMBL5082573

Cc1ccccc1CCNC(=O)C1CC1.O=CO

nearest known ligand 0.53

Full drug profile on Sugi Atlas →

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 2/20 0.53
BCHE P06276 2/20 0.53
ACHE P22303 2/20 0.53
THRB P10828 1/20 0.52
ALDH1A1 P00352 1/20 0.49
GAA P10253 1/20 0.49
MTNR1A P48039 5/20 0.49
KDM4E B2RXH2 1/20 0.47
HSD17B10 Q99714 1/20 0.47
TP53 P04637 1/20 0.47
MTNR1B P49286 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5071575 0.94 RXFP1 (0.57) RXFP1BCHEACHETHRBALDH1A1
Formic Acid SCHEMBL5085564 0.86 P2RX7 (0.54) RXFP1ALDH1A1GAATP53
Formic Acid SCHEMBL5073510 0.84 ALDH1A1 (0.57) RXFP1ALDH1A1GAAMTNR1ATP53
SCHEMBL18607398 0.83 MTNR1A (0.50) RXFP1BCHEACHETHRBALDH1A1
SCHEMBL5071517 0.79 P2RX7 (0.59) ALDH1A1GAAKDM4ETP53
Formic Acid SCHEMBL5076823 0.78 KDM4E (0.48) ALDH1A1MTNR1AKDM4EHSD17B10MTNR1B
Formic Acid SCHEMBL5082583 0.78 ALDH1A1 (0.49) ALDH1A1GAATP53
SCHEMBL29541881 0.78 BCHE (0.48) RXFP1BCHEACHETHRBALDH1A1
SCHEMBL2475349 0.78 ALDH1A1 (0.61) RXFP1ALDH1A1GAAMTNR1ATP53
Formic Acid SCHEMBL5071621 0.77 ALDH1A1 (0.64) THRBALDH1A1GAATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080312242-A1 7-ARYL-3, 9-DIAZABICYCLO(3.3.1)NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES ACTELION PHARMACEUTICALS, LTD. (CH) 2008-12-18 US disclosed
US-20050176700-A1 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension,cardiovascular or renal diseases ACTELION PHARMACEUTICALS LTD. (CH) 2005-08-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050176700-A1 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension,cardiovascular or renal diseases REN, AGTR1, ACE RXFP1 1095/4885BCHE 949/4885ACHE 1676/4885
US-20080312242-A1 7-ARYL-3, 9-DIAZABICYCLO(3.3.1)NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES REN, AGTR1, ACE RXFP1 1095/4885BCHE 949/4885ACHE 1676/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.